References
- WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition; 2021. [cited 2021 Dec 17]. Available from https://www.who.int/publications/i/item/9789240030824.
- Bouvard V, Wentzensen N, Mackie A, et al. The IARC perspective on cervical cancer screening. N Engl J Med. 2021;385(20):762–1918.
- Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect. 2020;26(5):579–583.
- Guidelines for primary HPV testing for cervical cancer screening in Malaysia. Family Health Development Division, Ministry of Health Malaysia. 2019. [cited 2021 Dec 20]. Available from https://www.ogsm.org.my/docs/GUIDELINES%20FOR%20PRIMARY%20HPV%20TESTING%20FOR%20CERVICAL%20CANCER%20SCREENING%20IN%20MALAYSIA.pdf.
- About the National Cervical Screening Program. Department of Health, Australian Governement. [cited 2021 Dec 20]. Available from https://www.health.gov.au/initiatives-and-programs/national-cervical-screening-program/about-the-national-cervical-screening-program.
- Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA A Cancer J Clin. 2020;70(5):321–346.
- Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103(4):619–631.
- Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst. 2005;97(12):888–895.
- Vijayaraghavan A, Efrusy MB, Mayrand MH, et al. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada. Can J Public Health. 2010;101(3):220–225.
- Felix JC, Lacey MJ, Miller JD, et al. The clinical and economic benefits of co-testing versus primary HPV testing for cervical cancer screening: a modeling analysis. J Womens Health. 2016;25(6):606–616.
- Petry KU, Barth C, Wasem J, et al. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with Annual Papanicolaou Cytology in Germany. Eur J Obstet Gynecol Reprod Biol. 2017;212:132–139.
- Tsu VD, Njama-Meya D, Lim J, et al. Opportunities and challenges for introducing HPV testing for cervical cancer screening in Sub-Saharan Africa. Prev Med. 2018;114:205–208.
- Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20):2158–2168.
- Darus N, Chandriah H, Lajis R. Health Technology Assessment Report: HPV DNA-based screening test for cervical cancer. Ministry of Health Malaysia. 2011. [cited 2021 Dec 20]. Available from https://www.moh.gov.my/moh/resources/auto%20download%20images/587f12c7011bb.pdf.
- Ronco G, Biggeri A, Confortini M, et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol Prev. 2012;36(3–4 Suppl 1):e1–72.
- Leopold C, Habl C, Vogler S. Tendering of pharmaceuticals in EU Member States and EEA countries: results from the country survey; 2008. [cited 2021 Dec 17]. Available from http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/Final_Report_Tendering_June_08.pdf.
- Maniadakis N, Holtorf AP, Otávio Corrêa J, et al. Shaping pharmaceutical tenders for effectiveness and sustainability in countries with expanding healthcare coverage. Appl Health Econ Health Policy; 2018;16(5):591–607.
- Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–257.
- Ted -Tender electronic daily. Supplement to the Official Journal. Available from: http://www.ted.europa.eu.
- Eurostat - The statistical office of the European Union. Available from: https://ec.europa.eu/eurostat.
- Giorgi Rossi P, Naldoni C, Di Stefano F, et al. Report MIDDIR – Methods for investments/disinvestments and distribution of health technologies in Italian Regions. Chapter 5. 2016. [cited 2021 Dec 20]. Available from: https://www.cpo.it/workspace/files/report-middir-aprile2016-571a18a7556a9.pdf.
- Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. Jama. 2002;287(18):2372–2381.
- den Ambtman A, Knoben J, van den Hurk D, et al. Analysing actual prices of medical products: a cross-sectional survey of Dutch Hospitals. BMJ Open. 2020;10(2):e035174.
- Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European Countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735–741.
- Shaw B, Mestre-Ferrandiz J. Talkin' about a resolution: issues in the push for greater transparency of medicine prices. Pharmacoeconomics. 2020;38(2):125–134.
- Perehudoff K, Mara K, Hoen E. WHO Health Evidence Network Synthesis Report, No. 73 – What is the evidence on legal measures to improve the transparency of markets for medicines, vaccines and other health products (World Health Assembly resolution WHA72.8); 2021.
- Hussain R, Bukhari NI, Ur Rehman A, et al. Vaccine prices: a systematic review of literature. Vaccines. 2020;8(4):629.
- Barbier L, Simoens S, Soontjens C, et al. Off-Patent biologicals and biosimilars tendering in Europe-a proposal towards more sustainable practices. Pharmaceuticals. 2021;14(6):499.
- Kastanioti C, Kontodimopoulos N, Stasinopoulos D, et al. Public procurement of health technologies in Greece in an era of economic crisis. Health Policy. 2013;109(1):7–13.
- Wouters OJ, Sandberg DM, Pillay A, et al. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period. Soc Sci Med. 2019;220:362–370.
- Ji Y. Can Competitive Bidding Work in Health Care? Evidence from Medicare Durable Medical Equipment. Harvard University. 2021. [cited 2022 May 21]. Available from: https://scholar.harvard.edu/files/yunan/files/dme.pdf.
- Garattini L, van de Vooren K, Curto A. Pricing human papillomavirus vaccines: lessons from Italy. Pharmacoeconomics. 2012;30(3):213–217.
- Qendri V, Bogaards JA, Berkhof J. Pricing of HPV vaccines in European tender-based settings. Eur J Health Econ. 2019;20(2):271–280.
- Woo YL, Gravitt P, Khor SK, et al. Accelerating action on cervical screening in Lower- and Middle-Income Countries (LMICs) post COVID-19 era. Prev Med. 2021;144:106294.
- Vorsters A, Bosch FX, Poljak M, et al. HPV prevention and control – The way forward. Prev Med. 2022;156:106960.
- IARC 2022. Cervical cancer screening. IARC Handb Cancer Prev. 18:1–456. [cited 2022 May 21]. Available from https://publications.iarc.fr/604.
- Iftner T, Becker S, Neis KJ, et al. Head-to-Head comparison of the RNA-Based aptima human papillomavirus (HPV) assay and the DNA-Based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol. 2015;53(8):2509–2516.
- Maggino T, Sciarrone R, Murer B, et al. Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice Pilot Program. Br J Cancer. 2016;115(5):525–532.